Cellect Biotechnology Ltd. – American Depositary Shares (NASDAQ:APOP) has been given a $14.00 target price by investment analysts at HC Wainwright in a note issued to investors on Friday. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target would indicate a potential upside of 40.14% from the stock’s previous close.
Separately, ValuEngine downgraded shares of Cellect Biotechnology Ltd. – American Depositary Shares from a “hold” rating to a “sell” rating in a research report on Friday, December 1st.
Shares of Cellect Biotechnology Ltd. – American Depositary Shares (APOP) traded up $0.18 during trading hours on Friday, reaching $9.99. 353,406 shares of the company were exchanged, compared to its average volume of 159,485. The firm has a market capitalization of $54.89 and a P/E ratio of -14.33. Cellect Biotechnology Ltd. – American Depositary Shares has a 1 year low of $2.94 and a 1 year high of $13.50.
Cellect Biotechnology Ltd. – American Depositary Shares Company Profile
Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.
Receive News & Ratings for Cellect Biotechnology Ltd. - American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellect Biotechnology Ltd. - American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.